Morgan Stanley's investment ratings and target prices for Chinese biopharmaceutical stocks (Table)

AASTOCKS
2026.03.03 02:30

Morgan Stanley published a research report, listing the investment ratings and target prices for Chinese biopharmaceutical stocks as follows:

Stock | Investment Rating | Target Price (HKD)

Genscript Biotech Corporation (01952.HK) | Market Perform | 55 HKD -> 44 HKD

INNOVENT BIO (01801.HK) | Overweight | 130 HKD

VISEN PHARMA-B (02561.HK) | Overweight | 80 HKD -> 50 HKD

ZAI LAB (09688.HK) | Overweight | 37.5 HKD -> 19.5 HKD

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer